People

Acrivon’s team is a rare blend of leading scientific pioneers and highly accomplished executives. The team is located at two Centers of Excellence in Boston and Lund/Copenhagen in Scandinavia leveraging regional expertise, infrastructure, and capabilities.

A global team based out of two key life science clusters

BOSTON, MA U.S.
Development & Commercialization Site
  • Drug and clinical biomarker assay development
  • Clinical trials
  • Market access
Lund/Copenhagen
Precision-Proteomics Site
  • Early drug programs and biomarker identification
  • Drug profiling and mechanism-of-action
  • Mass spectrometry

Meet the Senior Leadership Team

Peter Blume-Jensen, M.D., Ph.D.

CEO, President, Founder

Peter Blume-Jensen

M.D., Ph.D.
CEO, President, Founder

Peter Blume-Jensen, M.D., Ph.D. is Founder, President, and CEO of Acrivon Therapeutics, Inc. He has extensive experience in oncology R&D and oncogenic kinase signaling. From 2001 to 2008, Peter was Department Head at Serono, US and later at Merck & Co, Inc. where he established and led integrated oncology drug programs into the clinic. Since 2008 he was Vice President, Ext. Sci. Affairs and Global Therapeutic Area Advisor for Oncology at Daiichi Sankyo, Inc. He co-led the scientific due diligence and M&A resulting in the acquisition of Plexxikon. From 2010-2014 he was CSO for Metamark Genetics where he built R&D and a novel, scripted proteomics tissue imaging platform. Here he led 4 clinical studies culminating with the blinded validation and launch of ProMark®, an outcome-predictive prostate cancer biopsy test included under NCCN guidelines and coverage. From 2014 till 2018 Peter was CSO for XTuit Pharmaceuticals where he established a novel prodrug platform in collaboration with Dr. Jeremiah Johnson, MIT, now continued at Window Therapeutics. Peter is the inventor of the AP3 platform and the OncoSignature® patient selection method.

Peter serves on the SAB for several private biotech companies and academic institutions. His review “Oncogenic Kinase Signaling (Nature, 2001) is a citation classic in the field of clinical medicine. He received his M.D. from Copenhagen University Medical School, Denmark, his Ph.D. from The Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-Doctoral Fellowship under Tony Hunter at the Salk Institute, La Jolla, CA.

Rasmus Holm-Jorgensen

Chief Financial Officer

Rasmus Holm-Jorgensen

Chief Financial Officer

Rasmus Holm-Jorgensen is Chief Financial Officer at Acrivon Therapeutics, Inc. Previously, he was part of the founding team and Chief Strategy and Portfolio Officer of Kiniksa Pharmaceuticals since its inception in 2015 and through the IPO to the launch of its first product. Prior to Kiniksa, he was Group Vice President and General Manager at Synageva BioPharma, where he created a new business unit with a portfolio of multiple rare disease programs following the company’s IPO in 2011 and culminating in the company’s sale for $9 billion. From 2008 to 2011, Rasmus drove the successful turnaround of the global commercial audiology organization of the GN Group, a global leader in intelligent audio solutions. From 1996 to 2008, Rasmus worked for Novo Nordisk in Denmark, U.S., Brazil and Mexico, where he held positions of increasing responsibility within general management, economy and planning, portfolio analysis, investor relations for North America and finance for LATAM. Rasmus received an M.S. in Economics from the University of Copenhagen and has completed executive training at INSEAD, Stanford University and Harvard Business School.

Erick Gamelin, M.D., Ph.D.

Chief Medical Officer

Erick Gamelin

M.D., Ph.D.
Chief Medical Officer

Erick Gamelin, M.D., Ph.D. is Chief Medical Officer at Acrivon Therapeutics, Inc. From 2019 to 2021, he served as Chief Medical Officer at Step Pharma, a biotech focused on developing drugs in hematological malignancies. Previously he served as Vice-President at Dynavax Technologies focused on oncology vaccines and immune therapies, and prior to that at Macrogenics Inc., working with immune therapies and bispecifics. Before that, he held leadership positions in early development at the Oncology Vaccine department at Pfizer, and with Targeted Therapies at Amgen.

Erick is a Medical Oncologist and Pharmacologist, former Professor of Oncology, and CEO of a national university cancer center and hospital, the West Oncology Institute. He received the title of Chevalier in the National Order of Merit by the French Minister of Health. During his career in academia, he has led a research lab in oncogenomics and genetics, funded by the French NCI, focused on the mechanisms of acquired resistance of cancer cells. He received his PhD in molecular pharmacology from Bordeaux University and did his Post-Doc at the NIH, Molecular Therapeutics Section, Medical Oncology Branch. He has led 150 phase 1-3 oncology trials and coauthored over 150 articles in peer-reviewed international journals.

Kristina Masson, Ph.D.

Site Head, SVP Operations, Co-Founder

Kristina Masson

Ph.D.
Site Head, SVP Operations, Co-Founder

Kristina Masson, Ph.D. is Co-Founder and SVP, Operations at Acrivon Therapeutics, Inc. and President and Site Head of the company´s research subsidiary Acrivon AB located in Medicon Village, Sweden. Here she has established all infrastructure, heads all operations, and runs the phospho-proteomic discovery hub and early drug programs for the company’s proprietary AP3 platform. In 2016 she founded and operated OncoSignature AB, a small biotech company focused on identifying predictive biomarkers for clinical-stage cancer therapeutics for US companies. OncoSignature’s business was subsequently acquired by Acrivon AB. Prior to that she was Principal Scientist at Merrimack Pharmaceuticals, Cambridge, MA where she co-led, managed, and participated in cross-functional teams in both preclinical and clinical-stage therapeutic antibody programs, designing projects to identify predictive biomarkers, combination strategies and resistance mechanisms. Before joining Merrimack Pharmaceuticals, Kristina was a Post-Doctoral Fellow in the Golub lab at the Broad Institute of MIT and Harvard, developing assays for novel therapeutics and automated high-throughput drug screening approaches centered around synthetic lethality in cancer. Kristina received her Ph.D. from Lund University, Sweden.

Eric Devroe, Ph.D.

SVP Business Operations

Eric Devroe

Ph.D.
SVP Business Operations

Eric Devroe, Ph.D. is SVP, Business Operations at Acrivon Therapeutics, Inc. Eric is an executive and entrepreneur with significant experience helping found, launch, and build new life science companies. Most recently, he served as Founder & CEO of Xione Therapeutics, Inc., an oncology focused spin-out of The University of Texas MD Anderson Cancer Center. Prior to Xione, he was the Founder and CEO of Opsonix, Inc., an infectious disease focused spin-out of the Wyss Institute at Harvard University. Prior to Opsonix, he served as Executive Director of Strategic Alliances at MD Anderson Cancer Center. Earlier in his career he served as VP, Business & Strategy Development at Metamark Genetics, Inc., and an Associate at Flagship Pioneering. He holds a B.S. in Microbiology from the University of Texas at Austin and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University.

Joon Jung, Ph.D.

Data Science

Joon Jung

Ph.D.
Data Science

Joon Jung, Ph.D., is VP and Head, Data Science at Acrivon Therapeutics, Inc. Previously, he was the VP and Head of Data Science and Translational Discovery at Theonys where he led data science, bioinformatics, computational chemistry, biophysics and structural biology activities. From 2012-2021, Joon was the Head of Informatics & Translational Science Lead at Cyclerion Therapeutics/Ironwood Pharmaceutical. During his tenure, he developed a suite of web-based bioinformatic applications and a systems biology platform to identify novel indications by integrating -omics data, pathways and protein-protein interactome. Earlier in his career, Joon was a scientist at Merck Research Laboratories, Johnson & Johnson and Triad Therapeutics. He holds a B.S. in Electrical Engineering from the University of Illinois, a Ph.D. in Computational Chemistry from U.C. Irvine and Hebrew University, and he completed his fellowship in Bioinformatics & Computational Biology at Columbia University.  

Mary Rose Keller

Clinical Operations

Mary Rose Keller

Clinical Operations

Mary Rose Keller is VP, Clinical Operations at Acrivon Therapeutics, Inc. Mary Rose has over 40 years of experience in clinical research and drug development beginning in academics as Director of Clinical Research Programs at the Cancer Research Institute, University of California, Davis and San Francisco. She subsequently worked with a CRO specializing in NDA submissions and completed approved submissions in HIV, Oncology, Biologic Response Modifiers, Pediatrics, and Imaging Technology. Mary Rose was recruited to Agouron Pharmaceuticals to lead operations for their first NDA for Viracept, which for many years was recognized for having fastest FIM to NDA approval. Following Agouron’s acquisition by Warner-Lambert and subsequent merger with Pfizer, Mary Rose was selected to create the global role of Development Operations Team Lead at Pfizer to provide operational support for all of Pfizer projects in development. Following her work with Pfizer, she gained additional experience in rare diseases with Shire, molecular diagnostics with Sequenom and Prometheus, viral vectors in brain tumors with Tocagen, and oncology supportive care and post-surgical pain management with Heron. She serves on the editorial board for Life Science Leader Magazine and is a frequent conference speaker. She graduated from UC Davis and attended leadership development programs at Wharton and UC San Diego.

Michail Shipitsin, Ph.D.

Biomarker Development

Michail Shipitsin

Ph.D.
Biomarker Development

Michail Shipitsin, Ph.D. is Executive Director, Biomarker Development at Acrivon Therapeutics, Inc. Michail has over 15 years of experience in translational and biomarker research and development. Previously, he headed biomarker development at Xtuit Pharmaceuticals with a focus on NASH liver disease and cancer. After joining the biotech industry, Michail led development of a first in kind multiplex immunofluorescence prognostic test for prostate cancer at Metamark Genetics.

Michail earned his Diploma in Molecular Biology from Novosibirsk State University. He completed Ph.D. in Biochemistry from Tufts University and conducted postdoctoral studies at Dana-Farber Cancer Institute with a focus on biomarkers in breast cancer.

Crystal Mercado

Human Resources

Crystal Mercado

Human Resources

Crystal Mercado is Global Head of Human Resources at Acrivon Therapeutics, Inc. Crystal has over 15 years of leadership experience in delivering innovative people solutions, developing HR infrastructure from the ground up, and helping to build high-performance cultures that promote diversity, equity, inclusion and belonging. Prior to joining Acrivon, Crystal served as Executive Director and Global Head of People & Culture at Kira Pharmaceuticals where she was a member of the senior leadership team, focused on a broad range of global strategic HR initiatives ranging from agile organizational design to employee lifecycle infrastructure for a fast-scaling company. Prior to Kira, Crystal was the Director of Human Resources at SpringWorks Therapeutics where she organized and built the human resources function during the transition of the company from small startup to a publicly-traded company. Crystal has also led the alignment of human resources strategy to business strategy during high-growth periods at Purdue Pharma as HR Business Partner and at Alexion Pharmaceuticals where she held positions as Talent Acquisition Specialist and Human Resources Associate. Crystal received her B.A. in Business Administration from Monroe College and continued her studies in Human Resources Employment Law at Pace University. She holds the Society for Human Resource Management – Certified Professional (SHRM-CP) designation.

James Dunyak, Ph.D.

Biostatistics

James Dunyak

Ph.D.
Biostatistics

James (Jim) Dunyak, Ph.D., is VP, Biostatistics at Acrivon Therapeutics, Inc. Previously, he was the Senior Director of Biostatistics at Certara. From 2015-2021, Jim served as the Senior Director of Clinical Pharmacometrics at AstraZeneca responsible for identifying opportunities to utilize innovative trial designs and statistical analysis methods in drug development. At Metamark Genetics, he held increasing roles of responsibility including most recently Head of Research and Development managing the R&D department. Earlier in his career, Jim held senior roles at Novartis, MITRE Corporation, and the Naval Research Laboratory. Additionally, he served as a tenured Associate Professor in the Department of Mathematics and Statistics at Texas Tech. Jim holds multiple degrees, including a B.S. from Virginia Tech, a M.S. in Engineering Mechanics from Virginia Polytechnic Institute, a Ph.D. in Applied Mathematics/Probability Theory from University of Maryland, a M.S. in Biostatistics from the Harvard T.H. Chan School of Public Health, and a M.S. in Regulatory Affairs from Northeastern University.

John van Duzer, Ph.D.

Chemistry Manufacturing and Controls

John van Duzer

Ph.D.
Chemistry Manufacturing and Controls

John van Duzer, Ph.D., is VP, CMC at Acrivon Therapeutics, Inc. John is a senior pharmaceutical industry executive with over 30 years of proven expertise in medicinal chemistry research, chemical development and GMP manufacturing of both active pharmaceutical ingredients and drug products. Prior to Acrivon, he was the SVP of Chemistry and Manufacturing at Acetylon. John is the inventor of Ricolinostat and Citarisnostat, selective HDAC6 inhibitors studied in the clinic for the treatment of multiple myeloma. When Celgene acquired Acetylon, he led the CMC tech transfer team that integrated Acetylon’s manufacturing processes into Celgene. Previously, while at Novartis, he invented Lumarcoxib, a marketed selective COX-2 inhibitor. At Eloxx Pharmaceuticals, he was the VP of Technical Operations responsible for all aspects of chemical development. He also served as the VP of Pharmaceutical Development and Manufacturing at Collegium Pharmaceuticals where he oversaw tech transfer of the commercial product Nucynta to a new manufacturing site. He is also the co-inventor of 36 patents and has co-authored 18 peer-reviewed scientific papers. John received his Ph.D. in Synthetic Organic Chemistry from Yale University, and B.A. in Chemistry from the University of Pennsylvania. 

Bruce Close

Quality and Compliance

Bruce Close

Quality and Compliance

Bruce Close is VP, Quality and Compliance at Acrivon Therapeutics, Inc. Previously, he was a Principal Quality Consultant at Halloran Consulting. From 2007 to 2020, Bruce served as Executive Director, Compliance Operations at Celgene, where he focused on GxP regulatory and healthcare compliance. Prior to Celgene, he was in Compliance and Quality at Schering Ag / Bayer directing quality improvement initiatives and GMP auditing and training. Bruce held a similar role at Regeneron with responsibility for GLP Quality Assurance. Earlier in his career, he was a scientist at Baxter. Bruce received a B.S. and a B.A. from Rutgers University and a M.S. in Jurisprudence from Seton Hall University.

Meet the Scientific Advisory Board

George Demetri, M.D., F.A.C.P., F.A.S.C.O., F.A.A.C.R.

Professor, Harvard Medical School; Co-Director, Ludwig Center; SVP, Experimental Therapeutics, DFCI

George Demetri

M.D., F.A.C.P., F.A.S.C.O., F.A.A.C.R.
Professor, Harvard Medical School; Co-Director, Ludwig Center; SVP, Experimental Therapeutics, DFCI

Dr. Demetri is Co-Director of the Ludwig Center at Harvard and Professor of Medicine at Harvard Medical School and serves as Senior Vice President for Experimental Therapeutics at the Dana-Farber Cancer Institute (DFCI). Dr. Demetri was instrumental in the development of Gleevec® (imatinib) as the first effective therapy for gastrointestinal stromal tumor (GIST) as a mutationally-driven solid tumor. His collaborative research efforts have contributed to worldwide regulatory approval of several other therapies, including sunitinib and regorafenib for GIST, as well as pazopanib, trabectedin, eribulin, and tazemetostat for other sarcomas. He is a member of the Board of Directors for Blueprint Medicines.

Dr. Demetri received his A.B. in Biochemistry at Harvard College and M.D. from Stanford Medical School. He completed his residency and chief residency at the University of Washington Hospitals in Seattle and his medical oncology fellowship at DFCI and Harvard Medical School. Dr. Demetri was the 2020 recipient of the David A. Karnofsky Memorial Award from the American Society of Clinical Oncology (ASCO).

Robert (Bob) Abraham, Ph.D.

EVP, Head of Cancer Biology, Odyssey Therapeutics; Adjunct Professor, UCSD; Adjunct Professor, Sanford Burnham Prebys Institute

Robert (Bob) Abraham

Ph.D.
EVP, Head of Cancer Biology, Odyssey Therapeutics; Adjunct Professor, UCSD; Adjunct Professor, Sanford Burnham Prebys Institute

Dr. Abraham is Executive Vice President and Head of Cancer Biology at Odyssey Therapeutics. Before that, he was most recently Chief Scientific Officer at Vividion Therapeutics. Prior to Vividion, he was the Senior Vice President and World-wide Head of the Oncology R&D group at Pfizer. From 2005-2009, he was the Head of Oncology Discovery Research at Wyeth. During his tenure at Wyeth and Pfizer, Dr. Abraham contributed to the development of eight FDA-approved cancer drugs. Prior to joining industry, Dr. Abraham was a Professor at the Sanford-Burnham-Prebys Medical Discovery Institute (SBPMDI) in La Jolla, CA, where he served as the Director of the NCI-designated SBPMDI Cancer Research Center. Prior to SBPDMI, he was endowed Chair in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center. Prior to Duke University, Dr. Abraham held dual professorships in the departments of Immunology and Pharmacology at the Mayo Clinic in Rochester, MN. He maintains Adjunct Professor appointments at U.C. San Diego (Department of Pharmacology), and at the Sanford Burnham Prebys Institute.

Dr. Abraham began his career as an Academic Investigator, with enduring interests in cancer biology and immunology. His major research interests included characterization and functional analysis of the mammalian Target of Rapamycin (mTOR) signaling pathway, cancer metabolism, cellular signaling and DNA damage responses. Dr. Abraham has authored over 225 scientific publications, and his published work has been cited over 48,000 times.

Dr. Abraham received his B.S. in Biology from Bucknell University and his Ph.D. in Pharmacology at the University of Pittsburgh, and he completed his postdoctoral training in Pharmacology and Immunology at the Mayo Clinic.

Timothy A. Yap, M.B.B.S., Ph.D., F.R.C.P.

Associate Professor, MD Anderson Cancer Center; Medical Director, Institute for Applied Cancer Science

Timothy A. Yap

M.B.B.S., Ph.D., F.R.C.P.
Associate Professor, MD Anderson Cancer Center; Medical Director, Institute for Applied Cancer Science

Dr. Yap is an Associate Professor in the departments for Investigational Cancer Therapeutics and Thoracic/Head and Neck Medical Oncology at the MD Anderson Cancer Center. He is also the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also an Associate Director of Translational Research at the Institute for Personalized Cancer Therapy, an integrated research and clinical trials program. Previously, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK.

Dr. Yap´s primary research focuses on development of targeted agents and their acceleration through biomarker-driven clinical trials. His main interests include targeting of the DNA damage response as well as the development of novel immunotherapeutics, and past and current he is and/or has been a Principal Investigator for multiple clinical trials evaluating novel strategies for targeting the DNA damage response in cancer. Dr. Yap obtained his B.Sc. degree in Immunology and Infectious Diseases at Imperial College London, UK, and subsequently went on to attain his medical degree from Imperial College London, UK. He has a Ph.D. in Molecular Pharmacology from the Division of Cancer Therapeutics at the Institute of Cancer Research, London, UK.

David Berman, M.D., Ph.D.

Professor and Chair, Department of Pathology and Molecular Medicine, Queens University

David Berman

M.D., Ph.D.
Professor and Chair, Department of Pathology and Molecular Medicine, Queens University

Dr. Berman is a Professor and Chair of the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario. He is board certified in Anatomic Pathology and practices urologic surgical pathology at Kingston Health Sciences Centre while also running a biomarker discovery laboratory focused on urologic cancers. Dr. Berman earned his M.D. and Ph.D. (Genetics and Development) degrees from the University of Texas, Southwestern Medical Center. He completed residency training and a postdoctoral research fellowship at Johns Hopkins where he established his independent research laboratory, which moved to Canada in 2012.

The Berman Laboratory focuses on basic, translational, and clinical aspects of prostate and bladder cancer. His research has helped identify bladder cancer stem cells and druggable targets in embryonic signaling pathways, and it has helped improve surgical pathology practice.

Dr. Berman was Director of the Queen’s Cancer Research Institute from 2015-2021 and has served on research advisory committees for the Canadian Cancer Society (ACOR), the Canadian Cancer Trials Group, and Bladder Cancer Canada. He currently leads a translational research effort for the Canadian Bladder Cancer Research Network.

Jesper Olsen, Ph.D.

Professor, University of Copenhagen; Academic Co-Founder, Head of Phosphoproteomics

Jesper Olsen

Ph.D.
Professor, University of Copenhagen; Academic Co-Founder, Head of Phosphoproteomics

Dr. Olsen is an Academic Co-Founder and Head of Phosphoproteomics at Acrivon Therapeutics, Inc. He is a Professor in Quantitative Proteomics at the University of Copenhagen and Vice Director of the Novo Nordisk Foundation Center for Protein Research. Dr. Olsen is a pioneer in mass spectrometry based phosphoproteomics and its applications to decipher cell-signaling networks at a systems-wide scale, and his research interest is developing and applying phosphoproteomics technologies for comprehensive kinase drug profilings with clinical actionability. Dr. Olsen is the most cited phosphoproteomics expert world-wide and among top 0.1% in protein sciences.

Dr. Olsen received his M.Sc. in Analytical Chemistry at the University of Southern Denmark and his Ph.D. in Biochemistry and Molecular Biology at the same place under the supervision of Professor Matthias Mann. Dr. Olsen completed his post-doctoral training in proteomics and cell signaling at the Max Planck Institute for Biochemistry in Munich. He is based in Copenhagen since 2009, where he joined the newly established Center for Protein Research, initially as Group Leader and since 2014 as Vice Director.

Meet the Board of Directors

Derek DiRocco, Ph.D.

Partner, RA Capital Management

Derek DiRocco

Ph.D.
Partner, RA Capital Management

Derek DiRocco is a Partner at RA Capital Management. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, and Werewolf Therapeutics. Previously, Derek covered solid tumor oncology landscapes.

Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis.

Sharon Shacham, Ph.D., M.B.A.

Chief Scientific Officer, Co-Founder, Karyopharm

Sharon Shacham

Ph.D., M.B.A.
Chief Scientific Officer, Co-Founder, Karyopharm

Dr. Shacham co-founded Karyopharm in 2008 and has served as their Chief Scientific Officer since December 2012. She was also President of Research and Development from December 2012 to April 2021. From 2010 to 2012, Dr. Shacham served as the Chief Scientific Officer and Head of Research and Development, and prior to that, as President and Chief Executive Officer. Dr. Shacham has led the scientific progress of Karyopharm since inception.

Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led the company’s efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials.

Dr. Shacham holds a Bachelor of Science in Chemistry, a Doctor of Philosophy in Chemistry, and a Master of Business of Administration from Tel Aviv University.

Peter Blume-Jensen, M.D., Ph.D.

CEO, President, Founder

Peter Blume-Jensen

M.D., Ph.D.
CEO, President, Founder

Peter Blume-Jensen, M.D., Ph.D. is Founder, President, and CEO of Acrivon Therapeutics, Inc. He has extensive experience in oncology R&D and oncogenic kinase signaling. From 2001 to 2008, Peter was Department Head at Serono, US and later at Merck & Co, Inc. where he established and led integrated oncology drug programs into the clinic. Since 2008 he was Vice President, Ext. Sci. Affairs and Global Therapeutic Area Advisor for Oncology at Daiichi Sankyo, Inc. He co-led the scientific due diligence and M&A resulting in the acquisition of Plexxikon. From 2010-2014 he was CSO for Metamark Genetics where he built R&D and a novel, scripted proteomics tissue imaging platform. Here he led 4 clinical studies culminating with the blinded validation and launch of ProMark®, an outcome-predictive prostate cancer biopsy test included under NCCN guidelines and coverage. From 2014 till 2018 Peter was CSO for XTuit Pharmaceuticals where he established a novel prodrug platform in collaboration with Dr. Jeremiah Johnson, MIT, now continued at Window Therapeutics. Peter is the inventor of the AP3 platform and the OncoSignature® patient selection method.

Peter serves on the SAB for several private biotech companies and academic institutions. His review “Oncogenic Kinase Signaling (Nature, 2001) is a citation classic in the field of clinical medicine. He received his M.D. from Copenhagen University Medical School, Denmark, his Ph.D. from The Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-Doctoral Fellowship under Tony Hunter at the Salk Institute, La Jolla, CA.

Kristina Masson, Ph.D.

Site Head, SVP Operations, Co-Founder

Kristina Masson

Ph.D.
Site Head, SVP Operations, Co-Founder

Kristina Masson, Ph.D. is Co-Founder and SVP, Operations at Acrivon Therapeutics, Inc. and President and Site Head of the company´s research subsidiary Acrivon AB located in Medicon Village, Sweden. Here she has established all infrastructure, heads all operations, and runs the phospho-proteomic discovery hub and early drug programs for the company’s proprietary AP3 platform. In 2016 she founded and operated OncoSignature AB, a small biotech company focused on identifying predictive biomarkers for clinical-stage cancer therapeutics for US companies. OncoSignature’s business was subsequently acquired by Acrivon AB. Prior to that she was Principal Scientist at Merrimack Pharmaceuticals, Cambridge, MA where she co-led, managed, and participated in cross-functional teams in both preclinical and clinical-stage therapeutic antibody programs, designing projects to identify predictive biomarkers, combination strategies and resistance mechanisms. Before joining Merrimack Pharmaceuticals, Kristina was a Post-Doctoral Fellow in the Golub lab at the Broad Institute of MIT and Harvard, developing assays for novel therapeutics and automated high-throughput drug screening approaches centered around synthetic lethality in cancer. Kristina received her Ph.D. from Lund University, Sweden.